Literature DB >> 26909147

Preclinical animal models of multiple myeloma.

Seint T Lwin1, Claire M Edwards2, Rebecca Silbermann3.   

Abstract

Multiple myeloma is an incurable plasma-cell malignancy characterized by osteolytic bone disease and immunosuppression. Murine models of multiple myeloma and myeloma bone disease are critical tools for an improved understanding of the pathogenesis of the disease and the development of novel therapeutic strategies. This review will cover commonly used immunocompetent and xenograft models of myeloma, describing the advantages and disadvantages of each model system. In addition, this review provides detailed protocols for establishing systemic and local models of myeloma using both murine and human myeloma cell lines.

Entities:  

Year:  2016        PMID： 26909147      PMCID： PMC4747080          DOI： 10.1038/bonekey.2015.142

Source DB:  PubMed          Journal:  Bonekey Rep        ISSN： 2047-6396


  51 in total

1.  Idiopathic paraproteinemia--a consequence of an age-related deficiency in the T immune system. Three-stage development--a hypothesis.

Authors:  J Radl
Journal:  Clin Immunol Immunopathol       Date:  1979-10

2.  Engineered nanomedicine for myeloma and bone microenvironment targeting.

Authors:  Archana Swami; Michaela R Reagan; Pamela Basto; Yuji Mishima; Nazila Kamaly; Siobhan Glavey; Sufeng Zhang; Michele Moschetta; Dushanth Seevaratnam; Yong Zhang; Jinhe Liu; Masoumeh Memarzadeh; Jun Wu; Salomon Manier; Jinjun Shi; Nicolas Bertrand; Zhi Ning Lu; Kenichi Nagano; Roland Baron; Antonio Sacco; Aldo M Roccaro; Omid C Farokhzad; Irene M Ghobrial
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-30       Impact factor: 11.205

Review 3.  A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease.

Authors:  J Paton-Hough; A D Chantry; M A Lawson
Journal:  Bone       Date:  2015-04-11       Impact factor: 4.398

4.  Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.

Authors:  Marta Chesi; Geoffrey M Matthews; Victoria M Garbitt; Stephen E Palmer; Jake Shortt; Marcus Lefebure; A Keith Stewart; Ricky W Johnstone; P Leif Bergsagel
Journal:  Blood       Date:  2012-03-26       Impact factor: 22.113

5.  Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease.

Authors:  S L Dallas; I R Garrett; B O Oyajobi; M R Dallas; B F Boyce; F Bauss; J Radl; G R Mundy
Journal:  Blood       Date:  1999-03-01       Impact factor: 22.113

6.  BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.

Authors:  Aldo M Roccaro; Antonio Sacco; Patricia Maiso; Abdel Kareem Azab; Yu-Tzu Tai; Michaela Reagan; Feda Azab; Ludmila M Flores; Federico Campigotto; Edie Weller; Kenneth C Anderson; David T Scadden; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

7.  Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease.

Authors:  Y W Huang; J A Richardson; A W Tong; B Q Zhang; M J Stone; E S Vitetta
Journal:  Cancer Res       Date:  1993-03-15       Impact factor: 12.701

Review 8.  A novel proteasome inhibitor NPI-0052 as an anticancer therapy.

Authors:  D Chauhan; T Hideshima; K C Anderson
Journal:  Br J Cancer       Date:  2006-10-23       Impact factor: 7.640

9.  The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis.

Authors:  Daniel R Carrasco; Kumar Sukhdeo; Marina Protopopova; Raktim Sinha; Miriam Enos; Daniel E Carrasco; Mei Zheng; Mala Mani; Joel Henderson; Geraldine S Pinkus; Nikhil Munshi; James Horner; Elena V Ivanova; Alexei Protopopov; Kenneth C Anderson; Giovanni Tonon; Ronald A DePinho
Journal:  Cancer Cell       Date:  2007-04       Impact factor: 31.743

10.  Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.

Authors:  G M Matthews; M Lefebure; M A Doyle; J Shortt; J Ellul; M Chesi; K M Banks; E Vidacs; D Faulkner; P Atadja; P L Bergsagel; R W Johnstone
Journal:  Cell Death Dis       Date:  2013-09-12       Impact factor: 8.469
View more
  15 in total

1.  The novel autophagy inhibitor elaiophylin exerts antitumor activity against multiple myeloma with mutant TP53 in part through endoplasmic reticulum stress-induced apoptosis.

Authors:  Gaoxiang Wang; Pan Zhou; Xing Chen; Lei Zhao; Jiaqi Tan; Yang Yang; Yong Fang; Jianfeng Zhou
Journal:  Cancer Biol Ther       Date:  2017-07-18       Impact factor: 4.742

2.  Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.

Authors:  Tan-Huy Chu; Manh-Cuong Vo; Hye-Seong Park; Thangaraj Jaya Lakshmi; Sung-Hoon Jung; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Cancer Immunol Immunother       Date:  2020-07-04       Impact factor: 6.968

3.  Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma.

Authors:  Fumou Sun; Yan Cheng; Susan A Walsh; Michael R Acevedo; Xuefang Jing; Seong Su Han; Michael D Pisano; Michael H Tomasson; Alan K Lichtenstein; Fenghuang Zhan; Parameswaran Hari; Siegfried Janz
Journal:  Haematologica       Date:  2019-06-20       Impact factor: 9.941

4.  O-GlcNAcylation homeostasis controlled by calcium influx channels regulates multiple myeloma dissemination.

Authors:  Parinya Samart; Sudjit Luanpitpong; Yon Rojanasakul; Surapol Issaragrisil
Journal:  J Exp Clin Cancer Res       Date:  2021-03-16

5.  Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model.

Authors:  Maaike V J Braham; Monique C Minnema; Tineke Aarts; Zsolt Sebestyen; Trudy Straetemans; Anna Vyborova; Jurgen Kuball; F Cumhur Öner; Catherine Robin; Jacqueline Alblas
Journal:  Oncoimmunology       Date:  2018-02-22       Impact factor: 8.110

Review 6.  Mouse models of multiple myeloma: technologic platforms and perspectives.

Authors:  Marco Rossi; Cirino Botta; Mariamena Arbitrio; Rosa Daniela Grembiale; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Oncotarget       Date:  2018-04-13

7.  Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma.

Authors:  Maaike Vj Braham; Anil K Deshantri; Monique C Minnema; F Cumhur Öner; Raymond M Schiffelers; Marcel Ham Fens; Jacqueline Alblas
Journal:  Int J Nanomedicine       Date:  2018-11-29

Review 8.  Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.

Authors:  Michael Pisano; Yan Cheng; Fumou Sun; Binod Dhakal; Anita D'Souza; Saurabh Chhabra; Jennifer M Knight; Sridhar Rao; Fenghuang Zhan; Parameswaran Hari; Siegfried Janz
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

9.  Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome: combined molecular and therapeutic studies.

Authors:  Lourdes Farre; Gabriela Sanz; Neus Ruiz-Xivillé; Manuel Castro de Moura; Juan Francisco Martin-Tejera; Samuel Gonçalves-Ribeiro; Maria Martinez-Iniesta; Monica Calaf; Jose Luis Mosquera; José Ignacio Martín-Subero; Isabel Granada; Manel Esteller; Eva Domingo-Domenech; Fina Climent; Alberto Villanueva; Anna Sureda
Journal:  Dis Model Mech       Date:  2021-07-15       Impact factor: 5.758

10.  Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma.

Authors:  Manh-Cuong Vo; Sung-Hoon Jung; Tan-Huy Chu; Hyun-Ju Lee; Thangaraj Jaya Lakshmi; Hye-Seong Park; Hyeoung-Joon Kim; Joon Haeng Rhee; Je-Jung Lee
Journal:  Front Immunol       Date:  2018-06-18       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.